What complications can happen with long-term Cosentyx (secukinumab) use?
Cosentyx (secukinumab) is an anti–IL-17A biologic used for chronic inflammatory diseases such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. With prolonged use, the main complication categories people and clinicians watch for are infections, worsening of specific immune-related conditions, and changes in how the immune system responds over time.
The most important long-term concern is infection risk. Because IL-17 plays a role in mucosal and skin defense, people on IL-17 inhibitors can be more susceptible to infections and may develop certain types of infections more easily than they would without the drug.
Can long-term use raise infection risk (including serious infections)?
Yes. Prolonged treatment can be associated with ongoing infection risk. In practice, this means clinicians monitor for symptoms of infection during treatment and reassess risk if someone has frequent infections or develops signs of a serious infection.
A specific infection type that gets particular attention with IL-17 blockade is mucocutaneous fungal infection (for example, fungal infections affecting skin or mucous membranes). Patients are generally advised to seek medical care if they develop persistent or worsening symptoms that could suggest a fungal infection.
Can Cosentyx worsen inflammatory bowel disease or trigger new GI symptoms?
Anti–IL-17 therapy has been linked to concerns about inflammatory bowel disease (IBD) worsening in some patients. That matters most for people who already have Crohn’s disease or ulcerative colitis, but it’s also a reason clinicians ask about GI symptoms during treatment and monitor over time.
If someone develops new or worsening symptoms such as ongoing diarrhea, abdominal pain, blood in stool, or unexplained weight loss while on Cosentyx, they should contact their clinician promptly.
Are there risks related to immune reactions or blood tests during extended treatment?
Over extended treatment, clinicians typically keep an eye on safety signals that may emerge with continued immune modulation. This can include monitoring for adverse reactions during therapy (for example, hypersensitivity/allergic reactions) and periodic review of overall health and infection history.
Routine lab monitoring requirements vary by condition and patient risk factors, but the key point for long-term complications is that safety is not “set and forget.” Ongoing monitoring and follow-up are usually part of long-term biologic treatment.
What happens if you stop Cosentyx after years—can complications occur?
Stopping Cosentyx usually affects symptom control rather than causing a direct “withdrawal complication,” but disease activity can return. For some patients, flares can happen as the medication effect wanes, which can indirectly increase risk of complications related to uncontrolled inflammation (for example, worsening skin disease burden, pain, and functional decline in arthritis).
Who should be especially cautious about prolonged Cosentyx use?
Extra caution is usually warranted if you have:
- A history of recurrent or serious infections
- Known chronic or recurrent fungal infections
- Pre-existing inflammatory bowel disease (Crohn’s disease or ulcerative colitis) or significant GI symptoms
- Significant immune system conditions or concurrent immunosuppressive therapies
Your prescriber may adjust the plan or monitor more closely based on these factors.
Are there alternatives if prolonged risks become a concern?
If infection risk, GI symptoms/possible IBD worsening, or other safety issues become a problem, clinicians may consider other systemic options for the underlying condition. Which alternative is appropriate depends on the disease (psoriasis vs. psoriatic arthritis vs. ankylosing spondylitis), prior responses, and your risk profile.
If you want, tell me which condition you’re taking Cosentyx for (psoriasis, psoriatic arthritis, or ankylosing spondylitis), how long you’ve been on it, and any symptoms you’re worried about, and I can narrow the “most relevant” long-term complication risks.
Sources
- DrugPatentWatch.com – Cosentyx (secukinumab)